James Valeriano, MD
Neurology · Pittsburgh, PANPI 1801898788
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $361,387 of the $416,487 with a category attached, or 86.8%. 18 manufacturers reported payments, led by SK Life Science, Inc. at 25.2% of the total. Among neurology clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 501 payments — averaging $831.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- SK Life Science, Inc.$105K
- UCB, Inc.$78K
- Jazz Pharmaceuticals Inc.$61K
- Neurelis, Inc.$52K
- Livanova USA, Inc.$42K
- Greenwich Biosciences, Inc.$36K
- plus $43K from 12 others
Across 97 payments — averaging $3069.39 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- UCB SA$116K
- Livanova USA, Inc.$114K
- Eisai Inc.$38K
- SK Life Science, Inc.$23K
- Sunovion Pharmaceuticals Inc.$7K
What the payments were for
- Consulting fees$23,0636%
- Speaking & faculty fees$361,38787%
- Travel & lodging$17,5134%
- Food & beverage$14,5083%
- Education$170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| SK Life Science, Inc. | 85 | $104,946 |
| UCB, Inc. | 76 | $77,636 |
| Jazz Pharmaceuticals Inc. | 44 | $60,991 |
| Neurelis, Inc. | 43 | $51,936 |
| Livanova USA, Inc. | 102 | $41,938 |
| Greenwich Biosciences, Inc. | 42 | $35,996 |
| Eisai Inc. | 35 | $16,935 |
| Catalyst Pharmaceuticals, Inc. | 11 | $9,145 |
| Sunovion Pharmaceuticals Inc. | 30 | $8,550 |
| Sumitomo Pharma America, Inc. | 5 | $5,855 |
| Supernus Pharmaceuticals, Inc. | 12 | $1,651 |
| Aquestive Therapeutics, Inc. | 1 | $450 |
| AbbVie | 9 | $177 |
| Biogen | 1 | $117 |
| Neuropace, Inc. | 2 | $101 |
| Genentech USA, Inc. | 1 | $23 |
| Medtronic | 1 | $23 |
| AstraZeneca | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Epidiolex$96,449
- XCOPRI$82,447
- VALTOCO$51,557
- Briviact$43,343
- Fycompa$25,572
- Nayzilam$21,946
- VNS THERAPY SENTIVA MODEL 1000 GENERATOR$21,453
- Cenobamate$21,297
- VNS Therapy$15,201
- APTIOM$14,314
- Fintepla$9,102
- VNS - Sentiva$4,236
- OXTELLAR XR$1,500
- LIBERVANT$450
- ADUHELM$117
How this compares
$416,487 in reported general payments places this provider in the 95th percentile of 941 neurology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EpidiolexCannabidiol (Cbd) | 255 | $1,607,196 |
| XcopriCenobamate | 590 | $909,815 |
| FinteplaFenfluramine Hcl | 52 | $859,152 |
| BriviactBrivaracetam | 281 | $354,951 |
| AptiomEslicarbazepine Acetate | 177 | $286,924 |
| Rufinamide | 144 | $210,262 |
| Lacosamide | 1,098 | $181,607 |
| TopamaxTopiramate | 85 | $144,588 |
| FycompaPerampanel | 105 | $121,593 |
| LamictalLamotrigine | 107 | $112,175 |
| KeppraLevetiracetam | 57 | $109,066 |
| ValtocoDiazepam | 89 | $105,276 |
| VimpatLacosamide | 90 | $101,528 |
| OnfiClobazam | 29 | $94,982 |
| BanzelRufinamide | 16 | $78,930 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| UCB, Inc.Fintepla, Briviact, Vimpat, Nayzilam | $77,636 | $1,383,151488 claims |
| SK Life Science, Inc.Xcopri | $104,946 | $909,815590 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $8,550 | $286,924177 claims |
| Eisai Inc.Fycompa, Banzel | $16,935 | $200,523121 claims |
| Neurelis, Inc.Valtoco | $51,936 | $105,27689 claims |
| Supernus Pharmaceuticals, Inc.Oxtellar Xr | $1,651 | $72,50654 claims |
| AbbVieQulipta | $177 | $18,80116 claims |
| Aquestive Therapeutics, Inc.Sympazan | $450 | $17,33112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 941 neurology providers in Pennsylvania.
Other neurology in Pittsburgh
- Anoopum GuptaPittsburgh$592K
- Thomas ScottPittsburgh$476K
- Amber van LaarPittsburgh$413K
- Andrea SynowiecPittsburgh$386K
- Dolores Dominguez SantamariaPittsburgh$265K
- Heather MouryPittsburgh$186K
- Troy DesaiPittsburgh$174K
- Richard KasdanPittsburgh$172K
- David LobasPittsburgh$158K
- Daniel KremensPhiladelphia$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.